Unrecognized tuberculosis in a patient with COVID-19

Stjepanović, Mihailo; Belić, Slobodan; Buha, Ivana; Marić, Nikola; Baralić, Marko; Mihailović-Vučinić, Violeta

doi:10.2298/sarh200730006s

Cited by 8 publications

(6 citation statements)

References 14 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most studies, leukopenia, particularly lymphocytopenia, was reported. In contrast, neutrophilic leukocytosis was observed in some studies (Garg and Im Lee, 2020;Singh et al, 2020;Mishra et al, 2021;Stjepanović et al, 2021).…”

Section: Laboratory Criteriamentioning

confidence: 90%

Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review

et al. 2022

View full text Add to dashboard Cite

BackgroundTuberculosis (TB) is still one of the most important causes of death worldwide. The lack of timely attention on TB diagnosis and treatment during the coronavirus disease 2019 (COVID-19) pandemic is a potential threat to health issues and may have severe consequences for patients and health systems. There is not much information on the management of TB during this period. Here, we reviewed the current literature to evaluate the rate of Mycobacterium tuberculosis and severe acute respiratory syndrome coronavirus 2 coinfections and interactions between these infectious agents.MethodsSeveral databases, including Web of Science, Scopus, and MEDLINE (via PubMed), were searched for original articles addressing TB and COVID-19 diseases published from December 2019 to April 2021.ResultsOf 3,879 articles, 57 articles were included in this study, and among 106,033 patients affected by COVID-19, 891 also had TB. Overall, investigators found a consistent increase in C-reactive protein, D-dimer (especially in patients with severe clinical manifestation), erythrocyte sedimentation rate, lactate dehydrogenase, alanine aminotransferase, and a reduction of lymphocytes. The respiratory symptoms of TB/COVID-19 patients were similar to those of TB patients, but the risk of developing pulmonary TB increased in COVID-19 patients. Also, the mortality rate in TB/COVID-19 patients was higher than that in patients affected only by COVID-19 or TB.ConclusionSome reports indicated worsening respiratory symptoms and even activation of latent TB after COVID-19 or vice versa. It seems that both active and previously treated TB constituted a risk factor for COVID-19 in terms of severity and mortality, regardless of other underlying diseases and patient status. Health systems should not neglect TB during this era of the ongoing COVID-19 pandemic by setting up appropriate diagnostic and clinical management algorithms.

show abstract

Section: Laboratory Criteriamentioning

confidence: 90%

Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Patients with chronic obstructive pulmonary disease and pulmonary emphysema are at higher risk of pneumothorax when infected with SARS-CoV-2 [19]. Signs suggestive of potential comorbidities on CRX might be obscured by signs of COVID-19 pneumonia [20]. However, in some cases, COVID-19 pneumonia changes might be so widespread that features suggestive of comorbidities are obscured.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 pneumonia complicated by late presentation of bilateral spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema

et al. 2021

View full text Add to dashboard Cite

Introduction. Over the last few months the coronavirus disease 2019 (COVID-19) pandemic has created overwhelming challenges for physicians across the world. While much has been described in the literature about lung infiltrates and respiratory failure associated with infection of coronavirus 2 (SARS-CoV-2), pneumothorax is reported as a rare (a rate of one percent) but life-threatening complication of COVID-19 pneumonia. Late bilateral spontaneous pneumothorax has been described in only few cases. The aim of the review is to consider pneumothorax as a possible complication of COVID-19 pneumonia, which is also one of the causes of respiratory deterioration and potentially fatal outcome in these patients. Case Outline. This article describes the clinical course of the patient who tested positive for SARS-CoV-2 on reverse-transcriptase polymerase chain reaction (RT-PCR) testing of nasopharyngeal and oropharyngeal swab specimens and who presented with COVID-19 pneumonia complicated by bilateral, spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema. He didn't have underlying lung disease or risk factors for pneumothorax, except administered NIV/CPAP during first hospitalization. The patient was successfully treated with surgical (chest drainage, thoracoscopy and pleural abrasion) and non-surgical methods (by application of drugs and other supportive therapies). Conclusion This review demonstrates that the possibility of a late pneumothorax should be kept in mind in patients with, or recovering from, COVID-19 disease with progressive dyspnea. The timely diagnosis and management of pneumothorax will reduce COVID-19 associated mortality.

show abstract

“…It is still unclear who, when or if will develop this complication. As of writing of this article, there are roughly 20 million infected people, with round 13 million who have recovered from COVID-19 infection [7,8]. How many of the recovered patients will have any complications, and if those complications are reversible, only time will tell.…”

Section: Discusionmentioning

confidence: 99%

Rapidly progressive pulmonary fibrosis in COVID-19 pneumonia

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction. COVID-19 pneumonia doesn?t have a characteristic course and prognosis. Many facts still remain hidden, mainly why certain patients develop complications with serious tissue damage and whether it causes a permanent organ impairment. If and when will fibrosis develop in COVID-19 pneumonia requires further research, but a link between the amount of tissue afflicted and the development of fibrosis exists. Case outline. A previously healthy, non-smoker, woman with minor symptoms on admission had suddenly developed a serious respiratory insufficiency and whose radiographic finding on computed tomography scan had shown a serious progression with the development of fibrosis in a matter of days. The exact mechanism and correlation of this clinical course remains unknown; however, it is clear that the pulmonary fibrosis is caused by COVID-19 pneumonia. Follow-up computed tomography scan, performed 50 days after initial symptoms, had shown a partial regression of consolidations and post-inflammatory fibrosis. Conclusion. Pulmonary fibrosis is the most severe complication of COVID-19 infection on the respiratory system. Who, when and if will develop any complication is still unclear, as well as if these changes are reversible? Also, the number of recovered patients who later develop any of the chronic complications remains to be seen.

show abstract

Unrecognized tuberculosis in a patient with COVID-19

Cited by 8 publications

References 14 publications

Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review

Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review

COVID-19 pneumonia complicated by late presentation of bilateral spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema

Rapidly progressive pulmonary fibrosis in COVID-19 pneumonia

Contact Info

Product

Resources

About